The UCL Technology Fund is dedicated to investing in intellectual property commercialisation opportunities arising from UCL’s world-class research base, focusing in particular on the physical and life sciences.

The Fund supports UCL in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical commercial application.

UCL Technology Fund

Congratulations to UCLTF portfolio company Echopoint Medical Ltd on it's £4.2 million Series A funding. 

The investment will support the company’s flagship iKOr system through the FDA approval process, setting the stage for its market debut in the United States.

We're delighted to continue our support for the UCL spinout, which is a leader in the development of advanced diagnostic solutions for cardiovascular care.

Dave Grimm, Partner UCL Technology Fund said: “It’s been great to partner with Echopoint right from their beginnings in the lab at UCL through to leading their Seed round and now supporting their Series A. We’ve been hugely impressed with the team’s ability to rapidly commercialise world leading university research and bring new fibre optic technology to deliver positive outcomes for end patients in the UK. We continue to support the company as they look to enter and scale across the US to help thousands suffering from microvascular disease.”

AlbionVC, UCL Business Ltd, Parkwalk Advisors, UCL Medical Physics & Biomedical Engineering, UCL Electronic and Electrical Engineering 

#SeriesAFunding #MedTech

Further information: https://bit.ly/42M1d2U

UCL academics looking to informally discuss topics relevant to research commercialisation. Don't miss the next I/O Lab Coffee Club event, taking place on 28 February. 

Ana Avaliani, Director of Enterprise at Royal Academy of Engineering, joins us as a guest speaker, to discuss the organisation’s commitment to entrepreneurship, and the challenges of translating research commercially.

UCL Business Ltd
UCL Computer Science
UCL Engineering

Learn more: https://lnkd.in/eMtwufT7

In celebration of International Day of Women and Girls in Science on 11th February, we chatted to UCLTF's Leigh Brody and Sara Watson, PhD.

Find out what makes their roles unique, working at the intersection of the life science and venture capital industry. 

Leigh and Sara share insights into what led them towards their career paths, and advice for the next generation of #WomenInSTEM & #WomenInScience.

AlbionVC UCL Business Ltd

Read more: https://lnkd.in/e-inCpPC

Read about some of the brilliant achievements to stem from commercialising UCL research and innovations in UCL Business Ltd's newly launched publication 'Impact'.  #UCLBImpact

UCLTF portfolio company, Bramble Energy Limited has designed, developed and deployed a unique marinised fuel cell system for use within a narrowboat – a first of its kind application. 

#hydrogen #FuelCells

Discover more about the project: https://lnkd.in/e-iVvNcq

UCLTF portfolio company Apollo Therapeutics has revealed that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5m: bringing the total raised in this round by the company during 2023 to $260m.

The Series C financing was led by Patient Square Capital and included participation by multiple new investors including M&G plc and two of the largest US public pension plans, along with existing investors including Rock Springs Capital.

Read More: https://lnkd.in/ey2Szdac

With the #cop28 climate talks taking place in Dubai, we took the opportunity to talk to Buffy Price, Interim CEO and Co-founder of Carbon Re, a growing business created from research at UCL’s Energy Institute, which aims to reduce industrial CO2 by gigatonnes, by using artificial intelligence.

Read More: https://lnkd.in/dGKGaGfK

Great news for UCLTF portfolio company Bramble Energy Limited! Congratulations on making the Deloitte UK Fast 50 and being named as Regional winner of the South East.
 
#UKFast50

Read more: 
https://bit.ly/49E8FjI

Good to see UCLTF’s Dave Grimm visiting Number 10, to hear more about the National Quantum Strategy.

“Businesses like Phasecraft demonstrate the incredible talent that we have in quantum computing in the UK. Great to hear how the government will be supporting the sector in the next phase.” David Grimm, Partner, UCLTF. 

AlbionVC
UCL Business Ltd

https://bit.ly/3rU4VK5

Euro

WordPress 6.1

British Server Location

David Grimm

Investment Director

Hazy is the world’s leading synthetic data company, re-engineering enterprise data so that it’s faster, easier and safer to use.

Freeline is a biotechnology company that develops transformative gene therapies for systemic debilitating diseases.

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.

Nozzle.ai is an eCommerce and advertising optimization platform for Amazon.

Bloomsbury AI enables everyone to easily create their own question-answering system.

England Investors

Investors Active in Reading, Reading

Europe Venture Capital Investors

Venture Capital Investors with Investments in East Coast

The UCL Technology Fund is dedicated to investing in intellectual property commercialisation opportunities arising from UCL’s world-class research base, focusing in particular on the physical and life sciences. The Fund supports UCL in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical commercial application.

UCL Technology Fund 2

London

England

United Kingdom

Europe

£10m seed round ‘to build AI data centres out of light’

UCL spinout Oriole raises £10m for low-energy AI LLM training

Oriole Networks Raises £10M in Seed Funding

London-based Oriole Networks raises €11.6 million to fast-train LLMs with AI ‘super-brains’

UCL spinout bags £10M to make AI ‘super brains’ for 100x faster LLM training

Bangladesh

Asia

Germany

UST is a competitor of UCL Technology Fund in the field of commercializing intellectual property.

Sutherland competes with UCL Technology Fund in the commercialization of intellectual property.

Sutherland

The UCL Technology Fund is a £50 million investment fund focused on commercializing intellectual property generated from UCL's world-class research base. It provides capital to spin-outs and start-up companies developing technologies in life and physical sciences, as well as in technology areas such as artificial intelligence and machine learning.

news impact assignment basic	general
public peers	general	Jun 24, 2024 11:07 PM	7cb1f6e4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jun 24, 2024 11:36 PM	3d1c1b94
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	af672aa0
crunchbase profile	general	Nov 25, 2024 9:18 AM	d862903f
li profile	general	Jun 24, 2024 11:07 PM	3c14d3bb
translate crunchbase fundingrounds	general	Nov 25, 2024 2:06 PM	60156b3a
peers	general
news basic	general	Jun 24, 2024 11:07 PM	8da4088c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

UK:CO:UCLTF

UCL Technology Fund